East Sunshine Medicine took 1.5 billion varieties of 24 new products on the way

Pharmaceutical Network November 19th, recently, Guangdong Dongsan Pharmaceuticals to imitate the 4 categories of declared for Grelo tablets were approved for production and as reviewed.
2019, China's public medical institutions terminal sales of more than 1.5 billion yuan, the original research manufacturer AstraZeneta accounted for more than 90% of the market share.
the current East Sunshine drug in the trial of the new classification of products have 24 species, hydrochloric acid fingomod capsules, Enta carpon tablets, etc. have not yet been approved for the first imitation.
triamcinolone is a new type of oral antiplatelet drug CPTP that can work directly without the need for liver metabolic activation.
the main dosage forms of Tigrello, which are currently listed in China, have tablets and dispersive tablets, of which dispersive tablets were approved for import in September this year. according to
meters of intranet data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sales of Grelo tablets more than 1.5 billion yuan, an increase of 48.85 percent year-on-year, of which the original research manufacturers accounted for more than 90 percent of the market share.
tu: Tigrello film evaluation source: Mi net consistency evaluation database including East Sunshine medicine, there are currently 9 domestic enterprises for Grelo tablets approved production and as reviewed, including Yangzijiang, Zhengda Tianqing, Xinlitai, stone medicine and so on.
with more and more generic drugs approved for the market, the market share of the original research manufacturers or gradually decreased. Table
: East Sunshine Pharmaceuticals in review of the new classification of product sources: MiNet MED2.0 China Drug Review Database Minet data show that Dongsian Pharmaceuticals submitted a new classification of generic drugs submitted for listing, 24 are still in review and approval, covering blood and hematognesis system, cardiovascular system, nervous system and other 7 treatment categories.
the first imitation of the hydrochloric acid fingomod capsule and entacarbon tablets has not been approved, of which the original products of the hydrochloric acid fingomod capsules will have global sales of more than US$3 billion in 2019.
addition, the domestic temporary no phosphate ostawe dry suspension agent listed for sale.
source: Mi Net database, state drug regulatory agency official website